Long term clinical outcome of chronic hepatitis C patients with sustained virological response to interferon monotherapy

Veldt, B. J.; Saracco, G.; Boyer, N.; Commà, C.; Bellobuono, A.; Hopf, U.; Castillo, I.; Weiland, O.; Nevens, F.; Hansen, B. E.; Schalm, S. W.
October 2004
Gut;Oct2004, Vol. 53 Issue 10, p1504
Academic Journal
Background: The key end point for treatment efficacy in chronic hepatitis C is absence of detectable virus at six months after treatment. However, the incidence of clinical events during long term follow up of patients with sustained virological response is still poorly documented and may differ between the Eastern and Western world. Aims: To assess clinical end points during long term follow up of European patients with a sustained virological response to interferon monotherapy. Methods: Meta-analysis of individual patient data from eight European protocolled follow up studies of interferon treatment for chronic hepatitis C. Results:A total of 286 sustained virological responders and 50 biochemical responders (detectable virus but normal alanine aminotransferase levels) were followed up for 59 months. Fifteen sustained virological responders (5.2%) had cirrhosis before treatment and 112 (39%) had genotype 1. The late virological relapse rate after five years of follow up was 4.7% (95% confidence interval (CI) 2.0-7.4) among sustained virological responders; all late relapses occurred within four years after treatment. Among sustained virological responders, the rate of decompensation after five years of follow up was 1.0% (95% CI 0.0-2.3) and none developed hepatocellular carcinoma (HCC). Survival was comparable with the general population, matched for age and sex, the standard mortality ratio being 1.4 (95% CI 0.3-2.5). Clinical outcome of patients with cirrhosis was similar to other sustained virological responders. For biochemical responders, the rates of development of decompensation and HCC during long term follow up were 9.1% (95% CI 0.5-17.7) and 7.1% (95% CI 0-15.0), respectively. Conclusions:Five year survival of European sustained virological responders was similar to the overall population, matched for age and sex. No HCCs were detected during long term follow up.


Related Articles

  • Haplotypes of Microsomal Epoxide Hydrolase and X-Ray Cross-Complementing Group 1 Genes in Indian Hepatocellular Carcinoma Patients. Kiran, Manjula; Chawla, Yogesh K.; Jain, Meenu; Kaur, Jyotdeep // DNA & Cell Biology;Nov2009, Vol. 28 Issue 11, p573 

    Hepatocellular carcinoma (HCC) is a life-threatening disease that is often associated with chronic infection by hepatitis B and C viruses. Genetic polymorphisms have been reported to alter the risk for HCC development. Genetic studies based on the haplotype have an increased power for detecting...

  • IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection. Sato, Masaya; Kato, Naoya; Tateishi, Ryosuke; Muroyama, Ryosuke; Kowatari, Norie; Li, Wenwen; Goto, Kaku; Otsuka, Motoyuki; Shiina, Shuichiro; Yoshida, Haruhiko; Omata, Masao; Koike, Kazuhiko // Journal of Gastroenterology;Apr2014, Vol. 49 Issue 4, p748 

    Background: IL28B polymorphisms were shown to be associated with a response to peg-interferon-based treatment in chronic hepatitis C (CHC) and spontaneous clearance. However, little is known about how this polymorphism affects the course of CHC, including the development of hepatocellular...

  • SUBCHRONIC TOXICITY OF PROPYL PARABEN IL-28B RS12979860 GENE POLYMORPHISM AS A PREDICTOR FOR HEPATOCELLULAR CARCINOMA IN EGYPTIAN PATIENTS WITH CHRONIC HCV GENOTYPE FOUR. Elsamanoudy, Ayman Z.; Abo El-Khair, Salwa M.; Abdelaziz Abdalla, Hussein; Besheer, Tarek; El-Alfy, Hatem A.; Metwali, Abdel Hameed A. // Egyptian Journal of Biochemistry & Molecular Biology;Dec2013, Vol. 31 Issue 2, p195 

    Hepatocellular carcinoma (HCC) is the fifth most common tumor worldwide. Hepatitis C virus (HCV) is largely responsible for the increase in incidence of HCC. There are few and controversial data available on the association between IL-28B single nucleotide polymorphisms (SNPs) and severity of...

  • US reports increase in liver cancer. Gottlieb, Scott // BMJ: British Medical Journal (International Edition);03/20/99, Vol. 318 Issue 7186, p755 

    Reports on the increase incidence of hepatocellular carcinoma in the United States. Percentage increase from 1976 to 1995; Main risk factors associated with hepatocellular carcinoma; Belief of many older Americans with hepatitis C on how the disease is contracted.

  • WNT Signaling Pathway Gene Polymorphisms and Risk of Hepatic Fibrosis and Inflammation in HCV-Infected Patients. Liu, Yanhong; El-Serag, Hashem B.; Jiao, Li; Lee, JuSeog; Moore, David; Franco, Luis M.; Tavakoli-Tabasi, Shahriar; Tsavachidis, Spiridon; Kuzniarek, Jill; Ramsey, David J.; White, Donna L. // PLoS ONE;Dec2013, Vol. 8 Issue 12, p1 

    Background:Chronic hepatitis C infection is the leading cause of hepatocellular carcinoma (HCC), a highly lethal malignancy with rapidly increasing prevalence in the United States. Little is known about genetic variations and HCC risk. This study aimed to determine if genetic variation in Wnt...

  • Contribution of Genome-Wide HCV Genetic Differences to Outcome of Interferon-Based Therapy in Caucasian American and African American Patients. Donlin, Maureen J.; Cannon, Nathan A.; Aurora, Rajeev; Jia Li; Wahed, Abdus S.; Bisceglie, Adrian M. Di; Tavis, John E. // PLoS ONE;2010, Vol. 5 Issue 2, p1 

    Background: Hepatitis C virus (HCV) has six major genotypes, and patients infected with genotype 1 respond less well to interferon-based therapy than other genotypes. African American patients respond to interferon α-based therapy at about half the rate of Caucasian Americans. The effect of...

  • Abnormalities identified in the liver after HCV eradication. Pockros, Paul J. // Infectious Disease News;Dec2011, Vol. 24 Issue 12, p19 

    The article discusses research from Japan which revealed histological abnormalities in noncancerous liver tissues of patients with hepatocellular cancer following hepatitis C (HCV) eradication.

  • Abnormalities identified in the liver after HCV eradication.  // Hem/Onc Today;12/10/2011, Vol. 12 Issue 23, p31 

    The article reports on the findings of a study by N. Aizawa and colleagues which showed the identification of histological abnormalities in noncancerous hepatic tissues of hepatocellular carcinoma patients following hepatitis C virus eradication, presented at the American Association for the...

  • Elevated expression and polymorphisms of SOCS3 influence patient response to antiviral therapy in chronic hepatitis C. Persico, M.; Capasso, M.; Russo, A.; Persico, E.; Crocè, L.; Tiribelli, C.; Iolascon, A. // Gut;Apr2008, Vol. 57 Issue 4, p507 

    Background: The response to antiviral therapy of chronic hepatitis C virus (HCV) infection is determined by virological, environmental and genetic factors. Objective: The hypothesis was tested that the expression of specific genes and their haplotype frequencies can differentiate between...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics